CliffBio
small molecule

VENLAFAXINE HYDROCHLORIDE

VENLAFAXINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyOsmotica Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand nameVENLAFAXINE HYDROCHLORIDE
Active ingredientVENLAFAXINE HYDROCHLORIDE
StrengthEQ 225MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2008
Marketing statusRX

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

VENLAFAXINE HYDROCHLORIDE patent cliff — loss of exclusivity — | CliffBio